Anti-IGFBP3 antibody (ab77635)
Key features and details
- Goat polyclonal to IGFBP3
- Suitable for: WB
- Reacts with: Human
- Isotype: IgG
Overview
-
Product name
Anti-IGFBP3 antibody
See all IGFBP3 primary antibodies -
Description
Goat polyclonal to IGFBP3 -
Host species
Goat -
Specificity
ab77635 is expected to recognize both reported isoforms (NP_001013416.1 and NP_000589.2). -
Tested applications
Suitable for: WBmore details -
Species reactivity
Reacts with: Human
Predicted to work with: Mouse, Rat, Horse, Cow, Dog
-
Immunogen
Synthetic peptide:
C-RYKVDYESQSTDTQN
, from the internal region of human IGFBP3 (NP_001013416.1; NP_000589.2). -
General notes
The Life Science industry has been in the grips of a reproducibility crisis for a number of years. Abcam is leading the way in addressing this with our range of recombinant monoclonal antibodies and knockout edited cell lines for gold-standard validation. Please check that this product meets your needs before purchasing.
If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, along with publications, customer reviews and Q&As
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles. -
Storage buffer
pH: 7.30
Preservative: 0.02% Sodium azide
Constituents: 0.5% BSA, 0.5% Tris buffered saline -
Concentration information loading... -
Purity
Immunogen affinity purified -
Purification notes
ab77635 is purified from goat serum by ammonium sulphate precipitation followed by antigen affinity chromatography using the immunising peptide. -
Clonality
Polyclonal -
Isotype
IgG -
Research areas
Associated products
-
Compatible Secondaries
-
Isotype control
-
Positive Controls
-
Recombinant Protein
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab77635 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
| Application | Abreviews | Notes |
|---|---|---|
| WB | (1) |
| Notes |
|---|
Application notes
Peptide ELISA: Use at an assay dependent dilution. Antibody detection limit dilution 1/64000.
WB: Use at a concentration of 0.02 - 0.06 µg/ml. Predicted molecular weight: 32 kDa.
Not yet tested in other applications.
Optimal dilutions/concentrations should be determined by the end user.
WB: Use at a concentration of 0.02 - 0.06 µg/ml. Predicted molecular weight: 32 kDa.
Not yet tested in other applications.
Optimal dilutions/concentrations should be determined by the end user.
Target
-
Function
IGF-binding proteins prolong the half-life of the IGFs and have been shown to either inhibit or stimulate the growth promoting effects of the IGFs on cell culture. They alter the interaction of IGFs with their cell surface receptors. -
Tissue specificity
Expressed by most tissues. Present in plasma. -
Sequence similarities
Contains 1 IGFBP N-terminal domain.
Contains 1 thyroglobulin type-1 domain. -
Developmental stage
IGFBP3 levels are higher during extrauterine life and peak during puberty. -
Domain
The thyroglobulin type-1 domain mediates interaction with HN. -
Post-translational
modificationsPhosphorylation sites are present in the extracelllular medium. -
Cellular localization
Secreted. - Information by UniProt
-
Database links
- Entrez Gene: 3486 Human
- Entrez Gene: 16009 Mouse
- Entrez Gene: 24484 Rat
- Omim: 146732 Human
- SwissProt: P20959 Cow
- SwissProt: P17936 Human
- SwissProt: P47878 Mouse
- SwissProt: P15473 Rat
see all -
Alternative names
- Acid stable subunit of the 140 K IGF complex antibody
- Binding protein 29 antibody
- Binding protein 53 antibody
see all
Images
-
Western blot - Anti-IGFBP3 antibody (ab77635)All lanes : Anti-IGFBP3 antibody (ab77635) at 0.02 µg/ml
Lane 1 : human breast cancer lysate (in RIPA buffer)
Lane 2 : human breast cancer lysate (in RIPA buffer) with immunizing peptide
Lysates/proteins at 35 µg per lane.
Predicted band size: 32 kDa
Observed band size: 28 kDa why is the actual band size different from the predicted?
Additional bands at: 50 kDa (possible non-specific binding)
The additional band of 50 kDa was consistently observed. However this band was not blocked by the immunizing peptide and it is therefore a non specific signal.
Datasheets and documents
-
SDS download
-
Datasheet download
References (6)
ab77635 has been referenced in 6 publications.
- Nery FC et al. Impaired kidney structure and function in spinal muscular atrophy. Neurol Genet 5:e353 (2019). PubMed: 31517062
- Bai R et al. The NF-?B-modulated miR-19a-3p enhances malignancy of human ovarian cancer cells through inhibition of IGFBP-3 expression. Mol Carcinog 58:2254-2265 (2019). PubMed: 31513316
- Yao TH et al. Propranolol induces hemangioma endothelial cell apoptosis via a p53-BAX mediated pathway. Mol Med Rep 18:684-694 (2018). PubMed: 29767244
- Marthandan S et al. Conserved genes and pathways in primary human fibroblast strains undergoing replicative and radiation induced senescence. Biol Res 49:34 (2016). PubMed: 27464526
- Goyal R et al. Antenatal maternal long-term hypoxia: acclimatization responses with altered gene expression in ovine fetal carotid arteries. PLoS One 8:e82200 (2013). WB ; Sheep . PubMed: 24367503
- Yoo EG et al. Insulin-like growth factor-binding protein-3 mediates high glucose-induced apoptosis by increasing oxidative stress in proximal tubular epithelial cells. Endocrinology 152:3135-42 (2011). WB ; Pig . PubMed: 21652730